Adagio Medical Holdings, Inc. filed a Form 8-K with the SEC on September 23, 2026, disclosing a workforce reduction and the commencement of a strategic alternatives review process.

Key Highlights

  • Workforce reduction: The company will reduce its workforce by 25 of 43 full-time employees, effective September 23, 2026.
  • Estimated cash costs: The company estimates approximately $1.3 million in cash expenditures, consisting primarily of one-time severance payments, benefits, and other related costs, excluding non-cash equity-based compensation charges.
  • Strategic alternatives: The company adopted a plan to extend its capital resources in connection with initiating a process to explore a full range of strategic alternatives.
  • Note conversion price change: The company notified holders of its 13% Senior Secured Convertible Notes that it would lower the Conversion Price to the Alternate Conversion Price for the period September 23, 2026 through October 31, 2026, subject to extension.
  • Alternate Conversion Price defined: Under the Notes, the Alternate Conversion Price is the lower of the Conversion Price then in effect and 85% of the lowest VWAP during the five consecutive trading days ending and including the trading day immediately preceding the applicable conversion notice.

Adagio Medical Initiates Restructuring and Strategic Review

According to the filing, Adagio Medical Holdings, Inc. (NASDAQ:ADGM) adopted a workforce reduction plan on September 23, 2026, as part of efforts to extend its capital resources while it explores strategic alternatives. The company disclosed that 25 of its 43 full-time employees would be affected, with the reduction taking effect immediately on the date of the report. The company estimated approximately $1.3 million in cash expenditures related to the reduction, consisting primarily of one-time severance payments, benefits, and other related costs, and specifically excluding non-cash charges associated with equity-based compensation.

The filing noted that the estimated costs and their timing are subject to a number of assumptions and that actual results may differ. The company also disclosed that it may incur additional charges or cash expenditures not currently contemplated, including potential impairment charges, though it stated it is not able to estimate the amount or range of such potential impairments as of the filing date. The company indicated it will amend the Form 8-K if and when management is able in good faith to estimate those charges.

Separately, the company disclosed a modification to its 13% Senior Secured Convertible Notes, notifying noteholders that the Conversion Price would be lowered to the Alternate Conversion Price for each date during the period from September 23, 2026 through October 31, 2026, subject to extension. The filing defined the Alternate Conversion Price as the lower of the then-current Conversion Price and 85% of the lowest volume-weighted average price (VWAP) of the common stock during the five consecutive trading days ending and including the trading day immediately preceding the applicable conversion notice. The company also stated it issued a press release on September 23, 2026, announcing its strategic alternatives process.

What Was Disclosed

Adagio Medical Holdings disclosed a plan to reduce its workforce by 25 of 43 full-time employees, estimated cash costs of approximately $1.3 million, a temporary reduction in convertible note conversion prices, and the commencement of a strategic alternatives review, all effective September 23, 2026.